Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3900558 A
Publication typeGrant
Publication dateAug 19, 1975
Filing dateOct 9, 1973
Priority dateJun 23, 1971
Publication numberUS 3900558 A, US 3900558A, US-A-3900558, US3900558 A, US3900558A
InventorsC Richard Kinsolving
Original AssigneeRichardson Merrell Inc
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method of measuring histamine release from mast cells
US 3900558 A
Images(6)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent Kinsolving 1 Aug. 19, 1975 METHOD OF MEASURING HISTAMINE Johnson, Amer. J. Physio. Vol. 216, 1969, pp.

RELEASE FROM MAST CELLS [75] Inventor: C. Richard Kinsolving, Cincinnati, Meta PSEBM, [953 455*457' Ohio Fawcett, J. Exptl. Med. Vol. 100, 1954, pp. 217-224.

[73] Assignee: Richardson-Merrell Inc., Wilton,

Conn Primary bxa'r'rtirier-Albert T. Meyers Assistant ExaminerAnna P. Fagelson Flledi 9, 1973 Attorney, Agent, or FirmL. Ruth Hattan; Eugene O. 21 1 Appl No; 404 44 Retter; George Rauchfuss, Jr.

Related US, Application Data 57 ABSTRACT [63] Continuation-impart of Ser. No. l56,()76 June 23, 1

1971. abandoned. The histamin'e'released by mast cells on contact with an allergen can be determined by measuring the up- [52] US. Cl. 424/8; 195/1 .7; 424/3; take by the mast cells ofa fluorescent acridone, which 424/ 12; 424/91 uptake is proportional to the amount of histamine re- [51] Int. Cl. ..G01n 21/38; GOln 31/22; leased by action of the antigen. Fluorescence of the GOln 33/16 acridone absorbed by the mast cells is measured in [58] Field of Search 424/3, 8, 12, 91; 195/].7 conventional manner and the amount of histamine released is determined thereby. [56] References Cited OTHER PUBLICATIONS 7 Claims, N0 Drawings METHOD OF MEASURING HISTAMINE RELEASE FROM MAST CELLS This application is a continuation-in-part of copending application Ser. No. 156,076 filed June 23, 1971, now abandoned.

BACKGROUND OF THE INVENTION The usual method of determining the sensitivity of humans to specific allergens is a long, tedious and expensive process which involves intradermal injection of various suspected allergens and, after a waiting period, observing the response to the injection. The extent of the wheal and flare which follows the injection of an allergen to which the patient is sensitive is then evaluated by visual inspection by an allergist. Because of the very many different allergens to which the patient may be sensitive, it is often necessary for him to make additional visits to the allergists office for further tests for a complete diagnosis. While the procedure is usually painful and obnoxious to the patient, it is, on rare occa sions, extremely dangerous in that anaphylactic shock and death have followed such skin testing procedures in the case of highly allergic individuals.

It has been established that hypersensitivity to specific allergens resides in a special class of immunoglobulins, called lgE, which have the characteristic of fixing avidly to mast cells which are concentrated in the skin, lung and nasal mucosa. The tissue fixed antibody, also referred to as reagin, in combination with the specific allergen to which the patient may be sensitive, causes the release of histamine and other allergy mediators, which is responsible for the condition which the patient experiences when being subjected to an allergic reaction. It has also been established that human reaginic sera which contains lgE circulating antibodies will activate mast cells from rats in vitro and when these sensitized cells are contacted with suitable antigens, histamine is released.

The quantitative determination of the amount of histamine in human serum is a long and involved process. Samples of the serum must be diluted, centrifuged, and the serum assayed by the technique of Shore et al., J. Pharmacol. and Exp. Therap., 1959, 127, 182, or a suitable modification thereof. This proceudre involves a deproteinization with perchloric acid, repeated extractions with suitable solvents, and conjugation of the histamine with o-phthaldialdehyde to form a fluorophore. The histamine determination is then made by determining the degree of fluorescence of the preparation.

THE INVENTION The present invention is based upon my discovery that fluorescent aridones are strongly absorbed by intact mast cells from which histamine has been released under the influence of an antigen. The amount of an acridone that is absorbed is directly proportional to the amount of histamine that has been released by the mast cells. Thus, by measuring the amount of the fluorescent acridone that is absorbed by the mast cells, it is possible to quantitatively determine the amount of histamine that has been released by these same cells as a result of their contact with an allergen.

The process of determining the sensitivity of an individual to specific allergens in accordance with the present invention can be carried out by a general practitioner, a nurse or a laboratory technician. It does not require the services of a highly trained allergist. It is not necessary that the patient remain in the doctors office while a reaction to the allergen is taking place and observations made of the reaction. It is simply necessary that the patient present himself at a convenient time for withdrawal of a small amount of blood on which the various tests may be made. The determination of allergy by the process of the present invention requires less than one hour and can be carried out in a doctors office or hospital prior to administering drugs which might cause a severe allergic reaction in the patient, such as, for example, penicillin. Many tests for different allergens can be made simultaneously with the small amount of blood that has been donated by the patient. The cost of the procedure is relatively low, as is the equipment for conducting the tests. The results may be observed on a qualitative or qualtitative basis, whereby particularly dangerous allergens to the individual patient may be quickly determined.

SUMMARY OF THE INVENTION In brief, the invention comprises the steps of obtaining a sample of whole blood from the patient, permitting the blood to clot, and removing the serum, which may be stored in a refrigerator until ready for use. Meanwhile, apreparation of intact mast cells in a buffered saline solution is prepared. These mast cells may be from various sources, the most convenient being obtained from the abdominal cavity of mice. or rats. Intact mast cells frozen in glycerol may be used as a source of supply in practicing the invention.

A l-ml. aliquot of the mast cell suspension containing from 100,000 to 1,000,000 mast cells is pipetted into a test tube and a definite amount, conveniently one drop, that is, about 0.05 ml of the patients serum is added to each tube of the suspended mast cells and the preparation is allowed to incubate, preferably at 37C.

for about 3 minutes. A drop or about 0.05 ml of an allergen solution, many of which are commerically available, is added to the test tube containing the mast cells and the patients serum and the tube is incubated for an additional 3 minutes. 1 ml. of a dilute solution of an acridone is then added to the tube, thoroughly mixed and incubated for 10 to 20 minutes. The tube is then centrifuged at 200 gs for 5 minutes. The fluorescence of the liquid in the tube is then measured with suitable apparatus and compared with that of the control. The degree of fluorescence due to the acridone absorbed by the mast cells indicates the degree of sensitivity of the patient to the particular antigen used in the test. Obviously, many different allergens can be tested at the same time in individual tubes containing the mast cells, the patients serum, the allergen and the fluorescent acridone.

DESCRIPTION OF A PREFERRED EMBODIMENT Mast cells were obtained as follows:

Male rats (200-400 grams) of the Sprague-Dawley strain were anesthetized with ether and exsanguinated following decapitation. Mast cells were obtained by lavage of the peritoneal and pleural cavities with 8-10 in]. of buffered salt solution (pH 6.8-7.0). The standard medium employed consisted of: mM NaCl, 2.7 Mm KCl, 0.9 mM CaCl 3 mM NaH PO 3.5 mM KH PO 5.6 mM dextrose and 0.1% human serum albumin (fraction V, Nutritional Biochemicals).

The mast cells were isolated from other serous cavity cells by centrifugation into 35% Ficoll solutions by a modification (Johnson and Moran, Proc. Soc. Expt. Biol. Med. 123: 886, 1966) ofthe method of Uvniis and Thon, Exp. Cell Res. 18: 512, 1959. The resulting cell preparations consisted of 8090% mast cells.

The number of mast cells in each preparation was estimated by the method of Bray and Van Arsdale, Proc. Soc. Expt. Biol. Med. 106: 255, 1961, i.e., aliquots of cell suspension were diluted with toluidine blue (0. 1%.) in 0.9% NaCl in a white blood cell-counting pipette and the stained cells were counted in a hemocytometer.

Mast cells suitable for practicing the process of the present invention may be obtained from other sources. A more plentiful Supply of the cells may be obtained from the peritoneal cavity of mice which have been infected with a mastocytoma, as described by Dunn et al. J. Natl. Cancer Inst. 18, 587, 1957. The large quantities of mast cells which are grown intraperitoneally may be harvested and stored indefinitely by freezing in glycerol. When required, these cells can be thawed and reconstituted to the appropriate cell concentration for practicing the invention. Mast cells from still other sources, including the hamster, may also be, used. As noted above, the mast cells are used at a concentration of about 100,000 to 1,000,000 mast cells per test. The larger number of mast cells used per test will give more definitive results. These cells are usually suspended in about 1 ml. of a buffered isotonic salt solution containing calcium, sodium and other cations at a pH of 6.8 to 7.2. A suitable buffered isotonic salt solution is the well-known Hanks solution.

Only a small amount of the human serum is sufficient to activate the mast cells. For convenience, one drop of serum is used. The amount of serum may range from about 0.05 to 0.5 ml. To eliminate factors which might have a small adverse effect on the quantitative readings, it is preferred that the serum be filtered before being used to activate the mast cells. In order for the lgE antibodies of the serum to activate the mast cells completely, the preparation should be incubated for l to 5 minutes at temperatures between 30C. and 45fC. Preferred conditions are incubation for 3 minutes at 37C.

After the mast cells have been activated with the antibodies of the serum, a small amount of the desired allergen is added and the solution is incubated between 30C. and 40C. for a few minutes. These allergens, which are water-soluble extracts of allergenic substances such as the pollen of ragweed, timothy and trees, cat'dander, house dust, and various foods and drugs, are commercially available, and only a small amount, usually the amount recommended by the manufacturer of the extract for a single intradermal test, is added to the activated mast cell suspension. Generally about 0.05 ml of an allergen solution is empolyed.

The release of histamine by the mast cells is proportional to concentrations of the antigen with which they have been treated up to a certain limit. For example, 0.05 micrograms of Compound 48/80, a basic condensation product of p-methoxyphenylmethyl amine available from Burroughs-Wellcome, Tuckahoe, New York, which mimics antigen action on mast cells under certain conditions, will release nanomoles of histamine from 1,000,000 mast cells, and these cells will absorb about 0.2 nanomoles of 2,10-dimethylaminopropyl acridone. On the other hand, 1.0 micrograms of the same compound will release approximately 80 nanomoles of histamine from 1,000,000 mast cells, which in turn will absorb about 3.0 nanomoles of acridone. Although the ratio of histamine released to acridone up take remains constant for any concentration of antigen at an acridone concentration of any particular valve, higher concentrations of acridone solution give lower histamine release-acridone uptake ratios.

Any water-soluble absorbable acridone which fluoresces is suitable in practicing the invention. The acridone employed must be capable of penetrating the mast cell. Acridone itself and 2- l 0- dimethylaminopropyl acridone have been found to be particularly useful. These acridones fluoresce in l N hydrochloric acid at 4700 angstroms wave length when activated with light at 4000 angstroms. The fluorescence was found to be linearly related to the concentration over a range of about 0.3 to 15.0 mug/ml. (millimicrograms per milliliter).

Although the uptake of allergen by the mast cells and release of histamine is relatively rapid and only a short incubation period is required, the complete uptake of the acridone by the activated mast cells is somewhat slower. Some acridone is taken up almost immediately, even by unactivated mast cells. On the other hand, complete equilibrim uptake of acridone requires about 20 minutes. The temperature at which this occurs is not critical. Room temperature is satisfactory.

As indicated above, the uptake of acridone is in direct proportion to the amount of histamine released by the allergen up to certain maximum limits. Acridone itself will not release histamine from mast cells, but a relatively small amount of acridone is absorbed by the unactivated cells. For example, 1,000,000 mast cells will, in 20 minutes, absorb about 5 nanomoles of 2,10- dimethylaminopropyl acridone from a solution containing 50 micromoles of the compound and about 9 nanomoles from a solution containing micromoles of the same acridone. As will be see, the exact amount of acridone taken up is dependent on the concentration of acridone present in the solution. For this reason a control tube to which no antigen has been added is necessary. However, when histamine is released from the activated mast cells by action of an antigen far larger amounts of acridone are taken up by the mast cells and this augmented take-up is directly proportional to the amount of histamine released. For example, when 1,000,000 mast cells have been subject to the action of Compound 48/80, about 17 nanomoles of acridone is absorbed in 20 minutes from a solution containing 50 micromoles of 2, IO-dimethylaminopropyl acridone and when 1,000,000 mast cells are activated with the same amount of antigen and allowed to come to equilibrium with a solution containing 100 micromoles of 2,10- dimethylaminopropyl acridone, approximately 37 nanomoles of the acridone are taken up by the mast cells. The uptake of acridone is linearly related to the concentration of acridone present up to a concentration of about 500 fLM or 0.015% by weight. It is preferred that the acridone solution have a concentration of 50. to 100 ,uM. Concentration are not necessary. However, the solution should have a concentration greater than 5 uM when 1,000,000 mast cells are used per test so that the cells alone will not absorb all of the acridone.

it is essential that the mast cells remain intact during their treatment with the patient's serum, allergen and acridone, and accordingly conditions which tend to break up the cells are to be. avoided. The solutions should be isotonic. Heat or cold should be avoided. The test procedures should take place between 3045C. Reagents which tend to lyse the cells or physical forces which might break up the cells are also to be avoided.

proximately 100,000 mast cells in Hanks solution is incubated with approximately 0.05- ml of serum for.5 minutes at 37C after which approximately 0.05 ml of the antigen is added and mixed. Followed by the addi- The hydrogen ion concentration should be close to pH 5 tion of 1.0 ml of a 5 X 101, M concentration of 2,10- 7.0. dimethylaminopropyl acridone. Incubation is contin-i After the treatment cells have been in contact with ued for 20 minutes. Each test solution is,then centrithe acridone solution for 10 to minutes, the suspenf d, a d th di m d ll are .l d d he sion is centrifuged at relatively low gravity, for examfluoresence measured in the manner described hereinple, about 200 gs for 5 minutes, the supernatant is re- 10 before. The values contained in columns 3 through 8 of moved, the tubes inverted and drained, and the mast Table 1 represent the uptake of acridone in response to v cells, which have been thrown out of the solution, are histamine release as measured by the fluoresence of lysed for l to 5 minutes with 1 ml. of 1 N hydrochloric each test solution and are expressed in nanomoles of acid. As a matter of fact, however, the mast cells may the acridone uptake per 100,000 mast cells. The allerbe lysed by other means, even distilled water. Hydrol5 gens employed in each test are commercially available chloric acid is preferred as its use enhances the fluoresand in each test 0.05 ml of the allergen solution precence of the acridone. pared in the manner prescribed by the commercial The fluorescence of the liquid in the tube is then source is used. These data indicate'that in each inmeasured and compared with that of the control. If the stance of known allergen sensitivity a significant patients serum has contained lgE antibody to a specific 20 amount of the acridone was absorbed by the mast cell.

TABLE 1 Test Known Allergen Egg Mixed Mixed Mlxed Cat Mixed no. Sensitivity Albumin Ragweed Trees Molds Epithelial House Dust 1 Ragweed 0.54 2.89* 3.17* 0.64 0.50 0.48

Trees 2 Ragweed 0.54 2.34* 0.29 329* 0.47 0.42

Molds 3 Animal dander 0.51 0.54 0.27 0.60 273* 0.45

and hair 4 Ragweed 0.59 304* 231* 0.59 0.51 2.8l*

House dust Trees 5 None 0.56 0.50 0.33 0.58 0.49 0.41

(control) =Eslablished difference from control.

allergen tested, histamine will have been released from Although the process of the present invention will the mast cells and the acridone absorbed, much more probably find its greatest usage in the determination of than would be expected if no histamine had been re- 40 allergies and drug sensitivities in humans, it is noted leased. The fluorescence of the solution due to the acrithat many warm-blooded animals also suffer from allerdone which has been removed from the mast cells by gies and the procedure described herein is applicable the lysing procedure is measured in any convenient to the determination of such allergies in these susceptimanner. It is preferred, however, that light from a suitble animals. Many different tests on samples of the subable source having an activating band of 4000 angjects serum for different antigens may be conducted at stroms is first passed through a filter which blocks out the same time. 10 ml. of the subjects blood should be light having a wave length above 4100 angstroms. This enough for the testing of about different allergens. light is caused to pass through the solution which fluo- It will also be obvious that the procedure may be easily resces to a degree depending upon the amount of acriautomated, whereby the fluorescence is recorded on done in it. The fluorescent light may then be measured 50 paper to provide a permanent record which may be with a phototube which is sensitive at about 4700 angfiled along with the subjects medical history. strom. Preferably, the light is passed through a filter, I Claimi which allows light above 4000 angstroms to pass. Al- A method of determining the Susceptibility of a though it is preferred that a phototube sensitive to light subject to allergens which Comprises the Steps of ihcu' at a wave lgngth of 4700 angstroms such as a 1 p 2 bating mast cells with serum of the subject at temperaphototube be used, it will be apparent that for qualitahires of to cohtactmg the lhcubated mast tive determinations the fluorescence can be observed cells with an allergen and thereafter adding a dilute with the naked lution of an absorbable fluorescent acridone to the allergen treated cells and measuring the acridone ab- The following data summarized in Table l demonsorbed by the mast cells strate the uptake of acridone by sensitized mast cells in 2 The method f l i 1 in which 100 to response to histamine release as a result of incubation 1 000 000 mast cells are incubated f 1 to 5 minutes of the sensitized mast cell with various allergens. Tests with 005 to 0 5 f blood serum f a Subject 1 through 4 are carried out with serum from subjects 3, Th th d f l i 2 i hi h th t ll are known to be sensitive to certain allergens. The known ded in i otonic saline at a pH within the range allergen sensitivities are indicated in column 2. Test number 5 is carried out on serum from a subject of no known allergen sensitivities and serves as a control. In each test 1.0 ml of a mast cell solution containing ap- 6.8 to 7.2 while in contact with the blood serum. allergen and acridone.

4. The method of claim 1 in which the acridone absorbed by the mast cells is recovered therefrom by lysis the mast cells from the liquid in which they are suspended, lysing the mast cells to release the fluorescent acridone and measuring the fluorescence of said absorbed acridone.

6. The method of claim 5 in which the fluorescent acridone is 2,10-dimethylaminopropyl acridone.

7. The method of claim 5 in which the fluorescent acridone is acridone.

UNITED STATES PATENT AND TRADEMARK OFFICE GERTIFICATE 0F EORRECTION PATENT NO. 5,900,558 9 DATED August 19, 1975 |N\/ ENTOR( C. Richard Kinsolving lt is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Q Column 2, line 16 on a qualitative or qualitative; basi sM."

should read "H. on a qual itative or quantitative basis...

Signed and Scaled this 7 Twentieth Day of July 1976 [SEAL] Attest:

RUTH c. MASON c. MARSHALL DANN A IPSN'ng Office Commissioner ofParenrs and Trademarks

Non-Patent Citations
Reference
1 *Fawcett, J. Exptl. Med. Vol. 100, 1954, pp. 217-224
2 *Johnson, Amer. J. Physio. Vol. 216, pp. 453-459
3 *Kinsolving, Diss. Abs. Vol. 32B, 1971, pp. 1671-B
4 *Mota, PSEMB, Vol. 83, pp. 455-457
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3988115 *Sep 18, 1975Oct 26, 1976Modabber Farrokh ZDiagnostic method for determining pathological condition by antigen-combining capacity of lymphocytes
US4343782 *Apr 6, 1979Aug 10, 1982Shapiro Howard MCytological assay procedure
US4373932 *Jan 2, 1981Feb 15, 1983Akzona IncorporatedQuantitative and qualitative analysis; complexing
US4404181 *Oct 15, 1981Sep 13, 1983Cambridge Chemical Products, Inc.Extended-life tissue fixative composition and method of using the same
US4640897 *May 2, 1983Feb 3, 1987Institut PasteurImmunoanalysis of basophil-containing blood fraction for diagnosing parasitoses and allergies
US5476797 *Oct 13, 1993Dec 19, 1995Asahi Denkakogyo K.K.Process and apparatus for detecting sensitized leukocyte or antigen
US8420054Sep 18, 2009Apr 16, 2013The Procter & Gamble CompanyNoninvasive method for measuring histamine from skin as an objective measurement of itch
EP0265411A2 *Oct 21, 1987Apr 27, 1988Monsanto CompanyIn vitro method to detect allergic reactions to low molecular weight chemicals
WO1994012876A1 *Nov 25, 1993Jun 9, 1994Euro Dpc LtdAllergen/inflammatory testing and diagnosis
Classifications
U.S. Classification435/7.24, 435/392, 436/513, 436/800, 530/868, 435/968, 436/815
International ClassificationG01N33/50
Cooperative ClassificationY10S435/968, Y10S436/80, G01N33/5091, Y10S530/868, Y10S436/815
European ClassificationG01N33/50D4